Literature DB >> 6539966

Cisplatinum: effect of zinc acetate pretreatment on cellular uptake and interactions with cytosolic ligands.

R P Sharma.   

Abstract

Wistar rats were injected (i.p.) either with 5 mg cis-diamminedichloro-platinum-II (cis-DDP)/kg, or pretreated with Zn-acetate and then injected with cis-DDP. The Zn-pretreatment significantly increased the binding of Zn and Cu to both the renal and hepatic metallothioneins (MT), but the proportion of cytosolic Pt associated with MT in the kidney tissue was slightly reduced, and that in the liver showed no difference in comparison to rats treated with cis-DDP only. The results indicate that an increased MT biosynthesis by Zn-pretreatment may not correspondingly increase the binding of intracellular Pt to MT. In the Zn-acetate pretreated rats, the renal tissue and subcellular Pt levels were significantly lower (P less than 0.01) than that in untreated rats, although the liver levels showed practically no difference. It is suggested that Zn-acetate pretreatment prior to cis-DDP injection, may significantly reduce the cellular burden of Pt in the critical organ, the kidneys.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6539966     DOI: 10.1016/0300-483x(84)90036-2

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  3 in total

1.  Zinc acetate pretreatment ameliorates cisplatin-induced Sertoli cell dysfunction in Sprague-Dawley rats.

Authors:  L M Pogach; Y Lee; W Giglio; M Naumoff; H F Huang
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Experimental basis for increasing the therapeutic index of cis-diamminedicarboxylatocyclobutaneplatinum(II) in brain tumor therapy by a high-zinc diet.

Authors:  F Doz; M E Berens; C F Deschepper; D V Dougherty; V Bigornia; M Barker; M L Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.